LINC00261 downregulation is observed in cisplatin-resistant colon cancer cells, while LINC00261 upregulation reverses cisplatin resistance and enhances the cisplatin effects of this drug via inactivation of the β-catenin/WNT pathway [55]. This evidence concerns the gene LINC00261 and colonic neoplasm.